Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B

Exclusion Criteria

• •Hepatitis A,C,D,E or HIV infection.
• •Autoimmune hepatitis.
• •Hepatic cirrhosis.
• •Serum creatinine \> 1.5 × ULN or Ccr \< 50 ml/min, Haemoglobin \< 110g/L (male) or \< 100g/L (female), Platelet\< 80 E＋09/L, Serum albumin ≤ 32g/L, or Serum albumin/globulin (A/G) ≤0.9, Neutrophile granulocyte \< 1.0 E＋09/L, Prothrombin time\>ULN＋3 seconds, Cholinesterase\<2500U/L.
• •Hepatitic carcinoma or Alpha Fetal Protein (AFP) \> 100ng/ml
• •Patients with other severe diseases combined, which could affect the therapy.
• •Patients accepted other clinical trial within 6 months before the first administrated.
• •Patients accepted immunomodulating or anti-viral treatment within 6 months before the trial.
• •Patients with autoimmune disease.
• •Thymosin allergy.
• •Pregnant or breast feeding.